Clinical trials: Unspecified Childhood Solid Tumor, Protocol Specific
Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
RATIONALE: Chemoprotective drugs such as carboxypeptidase-G2 may protect normal cells from the toxic effects of chemotherapy. PURPOSE: Clinical trial to study the effectiveness of carboxypeptidase-G2 in treating nervous system…
- Conditions
- Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00018967
- Testing
- glucarpidase
- Where
- 103 sites in United States, Australia and 2 more
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor
This phase I clinical trial is studying the side effects and best dose of IMC-A12 in treating young patients with relapsed or refractory Ewing sarcoma/peripheral primitive neuroectodermal tumor or other solid tumors.
- Trial name
- NCT00609141
- Testing
- cixutumumab, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Bone Marrow Suppression, Fever, Sweats, and Hot Flashes
Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count
RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count.
- Conditions
- Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia
- Trial name
- NCT00003805
- Testing
- piperacillin sodium, piperacillin-tazobactam, tazobactam sodium
- Where
- 28 sites in United States, Belgium and 11 more
- Volunteers
- 859 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Unspecified Childhood Solid Tumor, Protocol Specific
Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070473
- Testing
- pemetrexed disodium
- Where
- 20 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- Children's Oncology Group
Fever, Sweats, and Hot Flashes, Infection
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
RATIONALE: Recombinant human mannose-binding lectin (MBL) may be effective in preventing infection in young patients with fever and neutropenia receiving chemotherapy for blood disease or cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00886496
- Testing
- recombinant human mannose-binding lectin
- Where
- 3 sites in United States
- Sponsor
- Enzon Pharmaceuticals, Inc.
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have advanced cancer and liver…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
- Trial name
- NCT00025415
- Testing
- imatinib mesylate, pharmacological study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Infection, Neutropenia
Anidulafungin in Treating Immunocompromised Children With Neutropenia
RATIONALE: Anidulafungin may be effective in preventing fungal infections in immunocompromised children who have neutropenia. PURPOSE: This phase I/II trial is studying the side effects of anidulafungin and to see how well it…
- Conditions
- Infection, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00068471
- Testing
- anidulafungin
- Where
- 5 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00107458
- Testing
- valproic acid
- Where
- 17 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Infection, Neutropenia
Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy
RATIONALE: Antibiotics, such as daptomycin and vancomycin, may be effective in treating bacteria in the blood. It is not yet known whether daptomycin is more effective than vancomycin in treating bacteria in the blood in patients…
- Conditions
- Infection, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00296049
- Testing
- daptomycin, vancomycin
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Diarrhea, Gastrointestinal Complications
Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy
RATIONALE: Cyclophosphamide may help control the symptoms of autoimmune enteropathy . PURPOSE: This phase II trial is studying how well cyclophosphamide works in treating young patients with severe autoimmune enteropathy.
- Conditions
- Diarrhea, Gastrointestinal Complications, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00258180
- Testing
- filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University
Brain and Central Nervous System Tumors, Lymphoma
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of rebeccamycin analogue in treating children who have solid tumors or non-Hodgkin's lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Trial name
- NCT00006102
- Testing
- becatecarin
- Where
- 226 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine
RATIONALE: Educating health providers on talking with cancer patients about complementary and alternative medicine (CAM) may help encourage health providers to talk more often with cancer patients about the use of CAM.
- Trial name
- NCT00608933
- Testing
- educational intervention, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 1,356 people
- Sponsor
- M.D. Anderson Cancer Center
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor
Irinotecan in Treating Children With Refractory Solid Tumors
This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Grade I Meningioma
- Trial name
- NCT00004078
- Testing
- irinotecan hydrochloride
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- Children's Oncology Group
Unspecified Childhood Solid Tumor, Protocol Specific
Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors
Phase I trial to study the effectiveness of tirapazamine plus cyclophosphamide in treating children who have refractory solid tumors.
- Trial name
- NCT00003288
- Testing
- filgrastim, cyclophosphamide, tirapazamine
- Where
- 28 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma
Sunitinib in Treating Young Patients With Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of sunitinib in treating young patients with refractory solid tumors.
- Conditions
- Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor
- Trial name
- NCT00387920
- Testing
- sunitinib malate, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging
- Where
- 17 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma, Unspecified Childhood Solid Tumor, Protocol Specific
Fenretinide in Treating Children With Solid Tumors
Phase I trial to study the effectiveness of fenretinide in treating children who have solid tumors that have not responded to standard therapy.
- Trial name
- NCT00003191
- Testing
- fenretinide
- Where
- 26 sites in United States, Australia
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Colon Cancer, Head and Neck Cancer
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
This clinical trial studies positron emission tomography (PET)/magnetic resonance imaging (MRI) in patients undergoing PET/computed tomography (CT).
- Conditions
- Colon Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma
- Trial name
- NCT01557881
- Testing
- magnetic resonance imaging with positron emission tomography scanning
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Case Comprehensive Cancer Center
Brain Tumor, Recurrent, Brain Tumor, Pediatric
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
The PIRATE study tests the experimental drug RRx-001 in combination with 2 chemotherapy drugs that are commonly used in patients with cancer. RRx-001 has been used alone and with other anti-cancer medicines in adults.
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Pediatric, Central Nervous System Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- PIRATE (NCT04525014)
- Testing
- RRx-001, Temozolomide, Irinotecan
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- EpicentRx, Inc.
Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
This phase I trial is studying the side effects and best dose of pazopanib hydrochloride in treating young patients with solid tumors that have relapsed or not responded to treatment.
- Conditions
- Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00929903
- Testing
- pazopanib hydrochloride, pharmacological study
- Where
- 14 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)